VAXIMM
Latest round
- Series B
Last raised
- Sep 2018
Total raised
- Undisclosed
Investors
- 1
About VAXIMM
Founded in 2008 and headquartered in Basel, Switzerland, VAXIMM AG develops cancer immunotherapies. The company has undergone a strategic shift, focusing on oral T-cell activators. The founder, Andreas Niethammer, has a background in pharmaceutical development.VAXIMM is focused on the development of innovative oral T-cell immunotherapies designed to combat various forms of cancer. Their core product offerings revolve around proprietary technology that enables the activation of T-cells in response to specific neoantigens, which are unique markers associated with tumors. The company's therapies aim to enhance the body's immune response against cancerous cells, addressing unmet needs in cancer treatment. VAXIMM’s products primarily target patients with solid tumors, providing an alternative option for those seeking less invasive treatment methods.VAXIMM's revenue structure is driven by partnerships and collaborations with pharmaceutical companies and research institutions focused on advancing cancer treatment. These transactions typically involve licensing agreements and research collaborations, where VAXIMM may receive upfront payments and milestone payments tied to the achievement of specific development stages. The company's flagship products, which are at the forefront of their research initiatives, are positioned within a framework that emphasizes clinical trial advancements and regulatory approvals.VAXIMM is strategically positioned for future growth, focusing on the development of new immunotherapies within the oncology space. The acquisition of VAXIMM's Neoantigen Vaccine Development Assets by NEC Oncoimmunity AS in March 2022 marks a pivotal moment in their research and development trajectory. The company plans to expand its market reach into additional regions, specifically targeting North America and Europe for broader access to patients by 2024.800 mn will support these initiatives, enhancing their capabilities in clinical trials and product development.
Who invested in VAXIMM
1 investor across 1 round
See all investors in VAXIMM
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Sep 20, 2018
Amount
Undisclosed
Investors
Questions about VAXIMM
Who invested in VAXIMM?
VAXIMM has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VAXIMM raised?
VAXIMM has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did VAXIMM last raise money?
VAXIMM's most recent round on record is a Series B, in Sep 2018.
What does VAXIMM do?
Founded in 2008 and headquartered in Basel, Switzerland, VAXIMM AG develops cancer immunotherapies.
Where is VAXIMM headquartered?
VAXIMM is headquartered in Basel, Switzerland.
Which VCs invest in companies like VAXIMM?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at VAXIMM's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like VAXIMM? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.